WO2019139032A1 - Composition inhibant la perte musculaire pour patients atteints d'un cancer - Google Patents

Composition inhibant la perte musculaire pour patients atteints d'un cancer Download PDF

Info

Publication number
WO2019139032A1
WO2019139032A1 PCT/JP2019/000337 JP2019000337W WO2019139032A1 WO 2019139032 A1 WO2019139032 A1 WO 2019139032A1 JP 2019000337 W JP2019000337 W JP 2019000337W WO 2019139032 A1 WO2019139032 A1 WO 2019139032A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
fatty acid
cancer
cancer patients
acid triglyceride
Prior art date
Application number
PCT/JP2019/000337
Other languages
English (en)
Japanese (ja)
Inventor
中村　健太郎
欣也 芦田
秀和 殿内
秋菜 笹山
Original Assignee
株式会社 明治
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社 明治 filed Critical 株式会社 明治
Publication of WO2019139032A1 publication Critical patent/WO2019139032A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to a composition for suppressing a decrease in muscle mass of a cancer patient, and a composition for reducing the rate of decrease in muscle mass of a cancer patient.
  • Non-Patent Document 1 a problem in the clinic.
  • Non-patent Document 2 Muscle loss associated with cancer continues to deteriorate unless the progression of the tumor is suppressed, and there may also be a deterioration in the nutritional status due to cancer treatments such as anticancer drugs and radiation (see, for example, Non-patent Document 2). Furthermore, if the weight or muscle mass of a cancer patient falls below a certain value, the cancer patient may not be able to receive anticancer drug treatment. Therefore, treatment that maintains the nutritional status and reduces the tumor without losing weight and muscle is desired (see, for example, Non-Patent Document 3).
  • cancer patients are known to actively take oral nutritional supplements and the like containing eicosapentaenoic acid (EPA) etc. and try to suppress the reduction of their own body weight and muscle mass.
  • EPA eicosapentaenoic acid
  • Japanese Patent Application Publication No. 2013-508411 provides cancer patients with up to 50% of the calories normally consumed, at least 50% of them, as a method of reducing cancer growth or cancer symptoms. A method is described comprising the steps of obtaining calories from fat and giving the patient a maximum of 500 kcal / day for the next predetermined period.
  • WO 2017/038101 describes compositions for treating cancer, including a high fat diet.
  • An object of the present invention is to provide a composition useful for maintaining cancer patient's nutritional condition, suppressing muscle loss in cancer patient, prolonging the life prognosis of cancer patient, and improving QOL.
  • the cancer patient muscle mass loss suppression composition is, for example, a high-fat low-carbohydrate composition, which comprises at least one fatty acid triglyceride of long chain fatty acid triglyceride and medium chain fatty acid triglyceride as a lipid, Carbohydrate is an active ingredient.
  • this cancer patient muscle mass loss suppression composition contains a protein, long-chain fatty acid triglyceride, medium-chain fatty acid triglyceride and carbohydrate, as an active ingredient.
  • the cancer patient muscle mass reduction inhibitory composition is a composition that suppresses the decrease in muscle mass of cancer patients literally, and provides dietary support in cancer treatment.
  • composition for suppressing muscle mass loss in cancer patients may contain protein, long chain fatty acid triglyceride, medium chain fatty acid triglyceride and carbohydrate as main components, protein, long chain fatty acid triglyceride, medium chain fatty acid It may consist only of triglycerides and carbohydrates.
  • composition refers to preparations such as liquid food, supplements and food additives, food and drink (excluding animals and plants itself) and food and drink compositions (including processed food and drink). Included are things that animals (including humans) can consume.
  • the present inventors have found that the above-mentioned composition for suppressing muscle mass loss in cancer patients has an effect of suppressing muscle loss associated with cancer.
  • a mouse transplanted with a colon cancer cell line is ingested with the composition for suppressing muscle mass loss of cancer patients according to the present invention
  • cancer compared to mice not ingested with the same composition.
  • this composition for suppressing muscle mass loss in cancer patients can also be referred to as "a composition that alleviates the rate of decrease in muscle mass in cancer patients".
  • the above-mentioned cancer patient muscle mass reduction inhibitory composition has an effect of suppressing a reduction in muscle mass of a cancer patient.
  • the lower limit of the weight ratio of lipid to total weight of protein and carbohydrate is not particularly limited in the above-mentioned composition for suppressing muscle mass loss in cancer patients, but is preferably 0 1, more preferably 1.0, still more preferably 2.0, particularly preferably 2.5.
  • the upper limit is not particularly limited, but is preferably 6.0, more preferably 5.5, still more preferably 5.0, and particularly preferably 3.5.
  • the composition for suppressing muscle mass loss in cancer patients contains at least one fatty acid triglyceride of long chain fatty acid triglyceride and medium chain fatty acid triglyceride as a lipid.
  • the fatty acid triglyceride may be mainly composed of at least one fatty acid triglyceride of long chain fatty acid triglyceride and medium chain fatty acid triglyceride, or is composed only of at least one fatty acid triglyceride of long chain fatty acid triglyceride and medium chain fatty acid triglyceride It is also good.
  • the lower limit of the ratio of the weight of the medium-chain fatty acid triglyceride to the weight of the long-chain fatty acid triglyceride is although not limited, it is preferably 0.1, more preferably 0.3, still more preferably 0.5, particularly preferably 0.7.
  • the upper limit thereof is preferably 2.0, more preferably 1.8, still more preferably 1.3, and particularly preferably 0.9.
  • a method of using a composition containing at least one fatty acid triglyceride of long chain fatty acid triglyceride and medium chain fatty acid triglyceride as a lipid, a protein and a carbohydrate as a composition for suppressing muscle mass loss in cancer patients "A composition containing long-chain fatty acid triglyceride and / or fatty acid triglyceride of at least one of medium-chain fatty acid triglyceride for use as a composition for suppressing muscle mass loss in cancer patients, protein and carbohydrate”, "long-chain fatty acid triglyceride as lipid and "A method of suppressing a decrease in muscle mass of a cancer patient by administering a composition containing at least one fatty acid triglyceride, a protein and a carbohydrate of medium chain fatty acid triglyceride to cancer patients”, "long-chain fatty acid triglyceride as lipid and medium chain Fatty
  • the present inventors have found that the above-mentioned cancer patient muscle mass loss suppressing composition can effectively suppress the reduction in muscle mass of cancer patients. For this reason, a cancer patient can suppress a reduction in his own muscle mass by an animal such as a human suffering from cancer continues to consume the cancer patient muscle mass loss suppressing composition.
  • FIG. 6 is a bar graph showing gastrocnemius muscle weights after 21 days of normal mice in the normal group, tumor-bearing mice in the tumor-bearing control group, and tumor-bearing mice in the KF group in Examples.
  • the cancer patient muscle mass reduction inhibitory composition according to the embodiment of the present invention is a composition that suppresses the reduction of muscle mass in cancer patients, more specifically, a composition that reduces the rate of decrease in muscle mass in cancer patients. It is mainly composed of long-chain fatty acid triglyceride and / or fatty acid triglyceride of medium-chain fatty acid triglyceride, protein and carbohydrate. In addition, it is preferable that this cancer patient muscle mass loss suppression composition is a composition of a high fat and low carbohydrate composition.
  • these components and compositions will be described in detail.
  • the protein is not particularly limited.
  • corn gluten, wheat gluten, soy protein, wheat protein, milk protein, animal protein obtained from meat or fish (including collagen) , Egg white, egg yolk etc. but milk protein is preferable.
  • Milk proteins are primates such as humans, monkeys, gorillas, baboons, chimpanzees, etc., mammals such as horses, cattle, buffalo, sheep, goats, pigs, camels, deer etc. domestic animals, dogs, cats and other companion animals Protein component contained in milk obtained from the above, preferably whey protein, casein and salts thereof and the like.
  • Whey protein is a protein component contained in milk whey, and representative components include ⁇ -lactalbumin ( ⁇ -La), ⁇ -lactoglobulin ( ⁇ -Lg), immunoglobulin and lactoferrin.
  • ⁇ -La ⁇ -lactalbumin
  • ⁇ -Lg ⁇ -lactoglobulin
  • immunoglobulin lactoferrin
  • part or all of the above components can be used as whey protein.
  • whey protein sweet whey, acid whey etc.
  • a concentrate thereof, a dried product thereof (whey powder etc.) and a frozen material thereof It can be used as whey protein.
  • desalted whey, whey protein concentrate (WPC) and purified whey protein (WPI) can also be used as whey protein in the cancer patient muscle mass loss suppression composition according to the embodiment of the present invention.
  • Casein is a type of protein contained in milk at a rate of about 80% by weight. Addition of acid to milk results in precipitation, which is casein.
  • the caseinate is not particularly limited as long as the addition to food is acceptable, and examples thereof include sodium caseinate, potassium casein, calcium casein and magnesium casein. Of these caseinates, sodium caseinate is preferred.
  • Casein sodium can be produced, for example, by reacting casein with sodium hydroxide or sodium hydrogen carbonate. Casein or caseinate is commercially available, and commercially available products may be used.
  • the lower limit of the amount of protein contained in the composition for suppressing muscle mass loss in cancer patients is not particularly limited, but preferably 5 g, more preferably 10 g, still more preferably 12 g, per 100 g of solid content of the composition. Particularly preferably, it is 14 g.
  • the upper limit is not particularly limited, but is preferably 30 g, more preferably 25 g, still more preferably 20 g, and particularly preferably 16 g.
  • the cancer patient muscle mass reduction inhibitory composition does not contain any protein, it has been found that it is preferable to include the protein in the cancer patient muscle mass reduction inhibitory composition. Protein is included.
  • the daily protein intake of the cancer patient is preferably in the range of 50 g to 80 g and 50 g to 70 g, assuming that the substantial weight (actual weight) of the cancer patient is 50 kg. It is more preferably in the range, still more preferably in the range of 55 g to 70 g, and still more preferably in the range of 60 g to 70 g.
  • the fatty acid triglyceride according to the embodiment of the present invention is a ketone body (containing at least one of acetoacetic acid and ⁇ -hydroxyacetic acid) which is an energy source by being decomposed in the cancer patient's body. It is produced and contains fatty acid triglyceride of at least one of long chain fatty acid triglyceride and medium chain fatty acid triglyceride.
  • This fatty acid triglyceride may consist mainly of at least one fatty acid triglyceride of long chain fatty acid triglyceride and medium chain fatty acid triglyceride, or consists only of at least one fatty acid triglyceride of long chain fatty acid triglyceride and medium chain fatty acid triglyceride May be
  • the lower limit of the ratio of the weight of the medium-chain fatty acid triglyceride to the weight of the long-chain fatty acid triglyceride is Although not limited, it is preferably 0.1, more preferably 0.3, still more preferably 0.5, particularly preferably 0.7.
  • the upper limit thereof is preferably 2.0, more preferably 1.8, still more preferably 1.3, and particularly preferably 0.9.
  • Medium-chain fatty acid triglyceride is also referred to as MCT (Medium Chain Triglyceride), and triglyceride having a medium length of constituent fatty acid, specifically, triglyceride having a carbon number of 6 or more and 12 or less It is.
  • the carbon number of the constituent fatty acid is preferably in the range of 8 or more and 12 or less, and more preferably in the range of 8 or more and 10 or less.
  • medium-chain fatty acids include, for example, hexanoic acid (caproic acid), heptanoic acid (enantanoic acid), octanoic acid (caprylic acid), nonanoic acid (pelargonic acid), decanoic acid (capric acid), dodecanoic acid (laurin) Acid) and the like.
  • the three medium chain fatty acids bound to one glycerol may be the same or different. When multiple types of medium-chain fatty acids bind to glycerol, the proportions thereof are not particularly limited.
  • the lower limit of the ratio of the amount of medium-chain fatty acid triglyceride in the fatty acid triglyceride is preferably 0 parts by weight, more preferably 20 parts by weight, still more preferably 30 parts by weight with respect to 100 parts by weight of total fatty acid triglycerides. Particularly preferably, it is 40 parts by weight.
  • the upper limit thereof is preferably 100 parts by weight, more preferably 80 parts by weight, still more preferably 70 parts by weight, and particularly preferably 50 parts by weight.
  • Medium-chain fatty acid triglycerides are present in the seeds of plants such as coconut and palm fruit, and in fats and oils contained in milk, dairy products and the like.
  • those extracted (including crude extraction) or purified (including crude purification) from such fats and oils can be used as medium-chain fatty acid triglycerides.
  • Such fats and oils are commercially available, and commercially available products may be used.
  • Long-chain fatty acid triglyceride is also referred to as LCT (Long Chain Triglyceride), and is a triglyceride having a relatively long length of constituent fatty acid, specifically a triglyceride having a carbon number of 13 or more and 30 or less. is there.
  • the carbon number of the constituent fatty acid is preferably in the range of 13 or more and 24 or less, and more preferably in the range of 13 or more and 18 or less.
  • long chain fatty acids include, for example, tetradecanoic acid, pentadecanoic acid, hexadecanoic acid, 9-hexadecenoic acid, octadecanoic acid, cis-9-octadecenoic acid, 11-octadecenoic acid, tetracosanoic acid, cis-15-tetracosanoic acid, Triacontanic acid etc. are mentioned.
  • the fatty acid may be unsaturated fatty acid.
  • the three long chain fatty acids bound to one glycerol may be the same or different. When multiple types of long chain fatty acids are bound to glycerol, their ratio is not particularly limited.
  • the lower limit of the ratio of the amount of long chain fatty acid triglyceride in fatty acid triglyceride is preferably 0 parts by weight, more preferably 30 parts by weight, and still more preferably 35 parts by weight with respect to 100 parts by weight of total fatty acid triglycerides. Particularly preferred is 50 parts by weight.
  • the upper limit thereof is preferably 100 parts by weight, more preferably 90 parts by weight, still more preferably 80 parts by weight, and particularly preferably 60 parts by weight.
  • long-chain fatty acid triglyceride is present in seeds of plants such as soybeans, rapeseeds and olives, and oils and fats contained in beef tallow and lard.
  • long-chain fatty acid triglyceride those extracted (including crude extraction) or purified (including crude purification) from such fats and oils can be used.
  • Such fats and oils are commercially available, and commercially available products may be used.
  • the lower limit of the content of fatty acid triglyceride in the composition for suppressing muscle mass loss in cancer patients is not particularly limited, but preferably 40 g, more preferably 50 g, still more preferably 55 g per 100 g of solid content of the composition. , Particularly preferably 70 g.
  • the upper limit is not particularly limited, but is preferably 100 g, more preferably 90 g, still more preferably 88 g, and particularly preferably 76 g.
  • the daily lipid intake of cancer patients is preferably in the range of 80 g to 200 g, assuming that the real weight (actual weight) of cancer patients is 50 kg, and 90 g to 190 g It is more preferably in the range, still more preferably in the range of 95 g to 170 g, still more preferably in the range of 100 g to 150 g, and particularly preferably in the range of 120 g to 140 g. .
  • Carbohydrates are carbohydrates which are not dietary fibers, and include monosaccharides, disaccharides and polysaccharides. Examples of monosaccharides include glucose (glucose), fructose (fructose), galactose and the like. Examples of disaccharides include maltose (malt sugar), sucrose (sucrose), lactose (lactose) and the like. As polysaccharides, starch (amylose, amylopectin), glycogen, dextrin and the like can be mentioned.
  • the carbohydrate preferably contains lactose, more preferably contains lactose but does not contain glucose, and still more preferably contains substantially only lactose.
  • the lower limit of the content of carbohydrate in the composition for suppressing muscle mass decrease in cancer patients is not particularly limited, but preferably 0.5 g, more preferably 2.0 g, per 100 g of solid content of the composition. More preferably, it is 5.0 g. Further, the upper limit thereof is not particularly limited, but is preferably 12 g, more preferably 11 g, further preferably 9 g.
  • the cancer patient's muscle mass loss-suppressing composition does not contain carbohydrates, it turned out that it is preferable to include carbohydrates in the cancer patient muscle mass-loss-inhibiting composition.
  • the substance contains sugar.
  • the daily carbohydrate intake of the cancer patient is preferably in the range of more than 0 g and 90 g or less, assuming that the substantial weight (actual weight) of the cancer patient is 50 kg, and more than 0 g and 60 g or less More preferably in the range of more than 0 g and 30 g or less, still more preferably in the range of 0 g and 20 g or less, and still more preferably in the range of 0 g and 10 g or less. preferable.
  • the daily carbohydrate intake of a cancer patient is 30 g or less, it is possible to induce the blood ketone body of the cancer patient, and as a result, it is preferable to improve the prognosis of the cancer patient.
  • the lower limit of the energy of the cancer patient muscle mass loss suppression composition is not particularly limited, but preferably 50 kcal / solid content 100 g, more preferably 80 kcal / solid content 100 g, still more preferably 100 kcal / solid content 100 g .
  • the upper limit is not particularly limited, but is preferably 1000 kcal / solid content 100 g, more preferably 900 kcal / solid content 100 g, still more preferably 800 kcal / solid content 100 g.
  • the cancer patient muscle mass loss suppression composition is preferably a composition having a high fat and low carbohydrate composition.
  • the "high fat and low carbohydrate composition” is a composition containing a large amount of lipids, as it is. And in the composition of this high fat low carbohydrate composition, it is preferable that, for example, 30% by weight or more of the solid content of the composition is a lipid.
  • the composition of this high fat low carbohydrate composition may be comprised only with the lipid.
  • fatty acid triglycerides of at least one of long chain fatty acid triglycerides and medium chain fatty acid triglycerides are particularly preferred.
  • the cancer patient muscle mass loss suppression composition according to the embodiment of the present invention exerts its function by being taken by a cancer patient, particularly a cancer patient having a muscle strength that can endure anti-cancer treatment and radiation treatment. Furthermore, although the cancer patient muscle mass loss suppression composition can work effectively also for terminal cancer patients if the above conditions are satisfied, it is preferable to use it for cancer patients with performance status (PS) 2 or less . This is because cancer patients with a performance status (PS) of 2 or less are patients for whom a normal diet can be performed without problems. In addition, as a "cancer patient” said here, arbitrary mammals can be mentioned.
  • the term "mammal” as used herein refers to, for example, rodents such as mice, rats, hamsters and guinea pigs, lagomorphs such as rabbits, ungulates such as pigs, cows, goats, horses and sheep, cats such as dogs and cats And primates such as humans, monkeys, rhesus monkeys, cynomolgus monkeys, marmosets, orangutans and chimpanzees.
  • the cancer patient is a human, it may be a human of a wide age group, from young to old, from an infant to an elderly person.
  • the cancer patient muscle mass loss suppression composition according to the embodiment of the present invention can be used by appropriately limiting carbohydrates to be compatible with diabetes.
  • cancer as used herein includes, for example, a tumor that develops as a result of mutation of a normal cell. Malignant tumors can arise from any organ or tissue throughout the body. In the present specification, the terms “cancer” and “malignant tumor” are used interchangeably unless otherwise specified.
  • cancer means, for example, lung cancer, esophagus cancer, stomach cancer, liver cancer, pancreas cancer, kidney cancer, adrenal cancer, adrenal cancer, biliary cancer, breast cancer, colon cancer, small intestine cancer, ovarian cancer, uterus cancer, uterus Body cancer, endometrial cancer, bladder cancer, prostate cancer, ureteral cancer, renal pelvis cancer, ureteral cancer, penile cancer, testicular cancer, brain tumor, cancer of central nervous system, cancer of peripheral nervous system, head and neck cancer, glioma And glioblastoma multiforme, skin cancer, melanoma, thyroid cancer, salivary adenocarcinoma, malignant lymphoma, carcinoma, sarcoma, leukemia and hematologic malignancy.
  • Lung cancer includes, for example, non-small cell lung cancer (eg, adenocarcinoma, squamous cell carcinoma, large cell cancer and the like), or small cell lung cancer.
  • the cancer patient muscle mass loss suppression composition according to the embodiment of the present invention is also effective for patients with terminal cancer including advanced cancer and metastatic cancer. The improvement of prognosis is very remarkable especially in patients with terminal cancer.
  • the cancer patient muscle mass loss suppression composition according to the embodiment of the present invention is particularly effective for brain tumors.
  • “ingestion” mentioned here is not limited as long as it enters the body of a cancer patient, and can be realized by, for example, all known intake methods such as oral intake, tube intake, enteral intake, and the like.
  • oral intake and enteral intake via the digestive tract may be mentioned, but oral intake is preferable, and oral intake by eating and drinking is more preferable.
  • the intake frequency is usually 3 times a day, but may be 2 times a day or 1 time a day depending on the case, and may be 4 times or 5 times conversely.
  • protein, fatty acid triglyceride and carbohydrate preferably occupy 100% by mass, and more preferably 95% by mass with respect to the total solid content. 90% by mass is more preferable, 80% by mass is more preferable, and 70% by mass is particularly preferable.
  • the weight per unit package of the cancer patient muscle mass loss suppression composition according to the embodiment of the present invention is not particularly limited, but from the viewpoint of being able to sufficiently obtain the effect and being easy to take it once,
  • the lower limit is preferably 25 g, more preferably 50 g, still more preferably 125 g, particularly preferably 130 g.
  • the upper limit is not particularly limited, but is preferably 400 g, more preferably 300 g, still more preferably 200 g, and particularly preferably 150 g.
  • the calorie amount of one meal is not particularly limited, but the lower limit is preferably 80 kcal, more preferably 100 kcal, still more preferably from the viewpoint that the effect can be sufficiently obtained and it is easy to take it once. It is 125 kcal.
  • the upper limit thereof is preferably 400 kcal, more preferably 300 kcal, still more preferably 200 kcal, and particularly preferably 150 kcal. In particular, it is most preferable to be in the range of 100 kcal or more and 500 kcal or less.
  • the calorie intake per day of the cancer patient muscle mass loss suppression composition does not fall below the basal metabolism of a human.
  • This basal metabolic rate can be calculated based on the substantial weight of the cancer patient by a known calculation formula or the like.
  • the Ministry of Health, Labor and Welfare According to the Japanese Dietary Intake Standard (2015 version), it is 21.5 kcal / kg body weight / day for men over 50 years old and 20.7 kcal / kg body weight / day for women over 50 years old
  • it is 24.0 kcal / kg body weight / day for men aged 18-29 and 22.1 kcal / kg body weight / day for women aged 18-29.
  • the above-mentioned unit packaging may be not only unit packaging per bag, a box, and a container, but may be unit packaging per unit contained in them, and may be unit packaging per day.
  • a plurality of days for example, an amount obtained by packaging a suitable quantity for intake for one week may be packaged, or a plurality of individual packages may be included.
  • the cancer patient muscle mass loss suppression composition according to the embodiment of the present invention is desirably taken continuously during cancer treatment.
  • the intake period is not particularly limited, and can be continued permanently.
  • the cancer patient muscle mass loss suppression composition according to the embodiment of the present invention can be used as a food and drink.
  • the food and drink are useful in that they have an effect of suppressing the decrease in muscle mass of cancer patients.
  • a single cancer patient muscle mass reduction inhibitory composition may be used, or two or more cancer patients Muscle mass loss inhibiting compositions may be used in combination.
  • the state thereof is not particularly limited, and solid, powder, semisolid, liquid, liquid, gel, paste Spray dried product, lyophilised product, vacuum dried product, drum dried product, liquid dispersed in medium, diluted product diluted with diluent, dried product in the form of crushed material in mill etc. be able to.
  • the cancer patient muscle mass loss suppression composition according to the embodiment of the present invention can be used as a food for patients (such as a cancer patient muscle mass loss suppression food).
  • the food for the sick may be in the form of a tablet, a capsule or the like.
  • the composition, the effect, the function, the type of the active ingredient, the type of the functional ingredient, the type of the functional ingredient, and the method of intake be displayed on the cancer patient muscle mass loss suppression composition according to the embodiment of the present invention.
  • the "indication” mentioned here should be a suitable indication in each of the quasi-drug, the functional food and the supplement.
  • the term “indication” as used herein includes all indications for informing the consumer of the above description.
  • This display may be any display that recalls or infers the above-mentioned display contents, and may include all display regardless of the purpose of display, the contents of display, the object / medium to be displayed, and the like. For example, displaying the above description on a product packaging / container, displaying or distributing the above description on an advertisement / price list or transaction document relating to the product, or electromagnetically (for example, the Internet) Provided by the method).
  • the product formed by packaging the composition for suppressing muscle mass decrease in a cancer patient according to an embodiment of the present invention is, for example, a food or drink
  • the food or drink includes, for example, It is preferable that a display such as "relaxation of muscle mass reduction rate of the patient" is attached.
  • the wording used in order to perform the above display is not limited to the above-mentioned example, You may be a wording synonymous with such a meaning. Such terms include, for example, for consumers, "suppress the decrease in muscle mass of cancer patients", “reduce the rate of decrease in muscle mass of cancer patients”, “muscle mass of cancer patients Various wordings can be tolerated, such as “helping to reduce the decrease in” or “help to reduce the rate at which the muscle mass of the cancer patient decreases.”
  • the cancer patient muscle mass loss suppression composition is, for example, orally or orally as a meal, a beverage, a nutrient, a supplement, a medicine or the like. It can be ingested through the tube (gastric fistula, intestinal fistula, transnasal tube). Specifically, liquid food, semi-liquid food, powdered food, jelly, gel, mousse, ice cream, shake, high energy supplement, high energy paste, meal alternative food and drink, care food, special purpose food, comprehensive nutrition food, It can be in the form of a dietary supplement, a food for specified health use, a food with functional indication, a processed food and the like.
  • liquid food, semi-liquid food, powdered food, jelly, gel, mousse, ice cream, shake, high energy supplement, high energy paste and more preferably, liquid food, semi-liquid food, powdered food, jelly, Gels, ice creams, high energy pastes, particularly preferably liquid foods, powdered foods, semi-liquid foods, foods for the sick, nutritional foods and the like.
  • the cancer patient muscle mass loss suppression composition according to the embodiment of the present invention as it is, but if it is not expected that the purpose of the present invention is impaired You may mix with food-drinks or a food component.
  • the shape of the food or drink is not particularly limited, as long as it is the shape of a commonly used food or drink.
  • it may be in any form such as solid (including powder and granular), paste, gel, liquid, suspension and the like, and is not limited thereto.
  • composition for suppressing muscle mass loss in cancer patients may be water, lipids other than long chain fatty acid triglyceride and medium chain fatty acid triglyceride, vitamins, minerals, as long as the purpose of the present invention is not impaired.
  • Ingredients contained in ordinary foods such as organic acids, organic bases, fruit juices, flavors, functional ingredients, food additives, etc. can be added.
  • lipid sources other than long-chain fatty acid triglyceride and medium-chain fatty acid triglyceride in the production of the above food and drink include, for example, lard, fish oil and the like, fractionated oils thereof, animal fats and oils such as hydrogenated oil and transesterified oil; And safflower oil, corn oil, rapeseed oil, coconut oil, fractionated oils of these, hydrogenated oils, vegetable fats and oils such as transesterified oil, and the like.
  • vitamins for example, vitamin A, carotenes, vitamin B group, vitamin C, vitamin D group, vitamin E, vitamin K group, vitamin P, vitamin Q, niacin, nicotinic acid, pantothenic acid, biotin, inositol, choline And folic acid and the like
  • minerals for example, calcium, potassium, magnesium, sodium, copper, iron, manganese, zinc, selenium and the like
  • examples of the organic acid include malic acid, citric acid, lactic acid and tartaric acid.
  • functional components include oligosaccharides, glucosamine, collagen, ceramide, royal jelly, polyphenol and the like.
  • the cancer patient muscle mass loss suppression composition according to the embodiment of the present invention may be any component having a cancer patient muscle mass loss suppression effect, such as eicosapentaenoic acid (EPA), branched chain amino acid (BCAA), etc. May be added.
  • EPA eicosapentaenoic acid
  • BCAA branched chain amino acid
  • the raw material may be any of natural products, processed natural products, synthetic products and / or foods rich in these.
  • these two groups are referred to as “tumor-bearing mouse group”
  • CDF1 mice belonging to the tumor-bearing mouse group are referred to as “tumor-bearing mice”.
  • CDF1 mice belonging to the normal group are referred to as "normal mice”.
  • tumor-bearing control group a group in which tumor-bearing mice are fed a purified feed for animals AIN-93G is referred to as a "tumor-bearing control group".
  • Meiji Ketone Formula 817-B composition: see Table 2; ketone ratio: 3
  • the tumor-bearing mice were dissected, and their weights and gastrocnemius weights were measured using an electronic balance. The results are shown in FIGS.
  • KF group a group in which a tumor-bearing mouse is fed with Meiji Ketone Formula (registered trademark) manufactured by Meiji Co., Ltd. is referred to as "KF group”.
  • the weight of normal mice in the normal group was significantly heavier than that of tumor-bearing mice in the tumor-bearing control group and those in the KF group at 21 days after the start of the test.
  • the weight of tumor-bearing mice in the KF group was significantly greater than the weight of tumor-bearing mice in the tumor-bearing control group.
  • the weight of normal mice in the normal group increased in 21 days, but the weight of tumor-bearing mice in the tumor-bearing control group and those in the KF group decreased in 21 days.
  • the weight loss of the tumor-bearing mice in the KF group was significantly less than the weight loss of the tumor-bearing mice in the cancer-bearing control group.
  • the total energy intake of tumor-bearing mice in the KF group from the start of the test to the 21st day elapsed is the total energy intake of tumor-bearing mice in the normal group and the tumor-bearing control group. It was significantly more than the amount.
  • the gastrocnemius muscle weight of the normal mice of the normal group at the 21st day after the start of the test is significantly more than that of the tumor-bearing mice of the tumor-bearing control group and the tumorigenic mice of the KF group Although heavy, the gastrocnemius muscle weight of the tumor-bearing mice in the KF group was significantly heavier than that of the tumor-bearing control mice. That is, it was possible to conclude that the rate of decrease in gastrocnemius muscle was alleviated in the tumor-bearing mice of the KF group that ingested Meiji Ketone Formula (registered trademark) manufactured by Meiji Co., Ltd.
  • composition for suppressing muscle mass loss in cancer patients according to the present invention is useful for prolonging the survival prognosis of cancer patients and improving QOL by maintaining the nutritional status of cancer patients and suppressing the decrease in muscle in cancer patients. is there.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention vise à proposer une composition qui inhibe la perte musculaire chez des patients atteints d'un cancer et est utile pour améliorer l'espérance de vie et la qualité de vie (QOL) des patients atteints d'un cancer. La composition inhibant la perte musculaire pour des patients atteints d'un cancer de la présente invention est, par exemple, une composition à teneur élevée en lipides et à faible teneur en hydrocarbures, et contient un triglycéride d'acide gras à longue chaîne et/ou un triglycéride d'acide gras à chaîne moyenne en tant que lipide, ainsi qu'une protéine et un saccharide. L'expression "composition inhibant la perte musculaire pour des patients atteints d'un cancer" signifie une composition qui inhibe littéralement la perte musculaire chez des patients atteints d'un cancer, et peut également faire référence à une composition qui ralentit la vitesse de perte musculaire chez des patients atteints d'un cancer. La composition inhibant la perte musculaire pour des patients atteints d'un cancer peut être uniquement composée d'une protéine, d'un lipide et d'un saccharide. Le terme "composition" est destiné à inclure des substances qui peuvent être ingérées par des animaux (y compris des êtres humains), telles que : des formulations comprenant des régimes à base de liquide, des compléments, des additifs alimentaires, et analogues ; des aliments et des boissons (autres que des animaux entiers et des plantes entières) ; et des compositions alimentaires et de boissons (y compris des aliments transformés et des boissons transformées).
PCT/JP2019/000337 2018-01-12 2019-01-09 Composition inhibant la perte musculaire pour patients atteints d'un cancer WO2019139032A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018-003185 2018-01-12
JP2018003185A JP2019123672A (ja) 2018-01-12 2018-01-12 癌患者筋肉量減少抑制組成物

Publications (1)

Publication Number Publication Date
WO2019139032A1 true WO2019139032A1 (fr) 2019-07-18

Family

ID=67218689

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/000337 WO2019139032A1 (fr) 2018-01-12 2019-01-09 Composition inhibant la perte musculaire pour patients atteints d'un cancer

Country Status (3)

Country Link
JP (1) JP2019123672A (fr)
TW (1) TW201929849A (fr)
WO (1) WO2019139032A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022113693A1 (fr) * 2020-11-30 2022-06-02

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017038101A1 (fr) * 2015-09-04 2017-03-09 国立大学法人大阪大学 Développement de thérapie diététique dans le cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017038101A1 (fr) * 2015-09-04 2017-03-09 国立大学法人大阪大学 Développement de thérapie diététique dans le cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHUKLA, S. K. ET AL.: "Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia", CANCER AND METABOLISM, vol. 2, no. 18, 2014, pages 1 - 19, XP021198226, ISSN: 2049-3002 *

Also Published As

Publication number Publication date
TW201929849A (zh) 2019-08-01
JP2019123672A (ja) 2019-07-25

Similar Documents

Publication Publication Date Title
JP4699901B2 (ja) 体脂肪代謝機能と燃焼エネルギーの活用機能とを備えているダイエット用添加物質
CA2715261C (fr) Produits alimentaires contenant des acides gras omega-3
ES2635764T3 (es) Método de producción de un producto alimenticio funcional basado en yema de huevo y productos obtenibles por el mismo
US20040157932A1 (en) Supplements and foods comprising oleylethanolamide
US10105401B2 (en) Composition comprising bioactive amino acids and/or peptides and marine oil in a stable oil-in-water emulsion, and the use of said composition as a functional or therapeutic composition
JPS6236645B2 (fr)
JP2008247748A (ja) 透析患者用栄養組成物
US20210260015A1 (en) Composition for inhibiting fat accumulation
TWI580362B (zh) Liquid nutrient composition
WO2019139032A1 (fr) Composition inhibant la perte musculaire pour patients atteints d'un cancer
KR20060024766A (ko) 혈중 저분자량질소함유화합물의 농도를 저감시키는질병개선용식품
JP2015164900A (ja) 満腹感持続剤および満足感を維持する方法
JP2021107400A (ja) 肥満抑制剤
JP7383874B2 (ja) エンドトキシンの血中移行阻害用組成物
WO2007132714A1 (fr) Agent servant à accroître la densité osseuse
WO2018123873A1 (fr) Composition pour favoriser la transpiration
WO2020158852A1 (fr) Composition permettant de favoriser la formation de corps cétoniques
JP2003261445A (ja) 血中中性脂肪低減剤
WO2018074415A1 (fr) Composition pour améliorer le coefficient d'efficacité protéique
JP2022056677A (ja) 貧血の予防又は治療用組成物、血中ヘモグロビン濃度の増加又は低下予防用組成物、及び血中赤血球数の増加又は低下予防用組成物
WO2024100178A1 (fr) Myo-inositol et prévention de la croissance accélérée
Mc Donagh et al. Milk and dairy products for better human health
JP2006025769A (ja) 健康食品および健康維持方法
Upadhay et al. In Touch

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19738825

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19738825

Country of ref document: EP

Kind code of ref document: A1